(02) 9850 4000 info@minomic.com
  • Linkedin
  • Twitter
  • Google
  • Linkedin
  • Twitter
  • Google
We are Minomic
  • Home
  • Company
    • Management
    • Board
    • Clinical Advisory Panel
    • Shareholder Information
    • Financial Statements
  • Diagnostics
  • Therapeutics
  • News
  • Contact Us
Select Page

Shareholder Information

Minomic Shareholder Update Q4 2017

Download PDF

Minomic Shareholder Update Q3 2017

Download PDF

Minomic Shareholder Update Q2 2017

Download PDF

Minomic Shareholder Update Q1 2017

Download PDF

RECENT POSTS

  • Minomic completes Prospective Clinical Study using MiCheck® to assist in diagnosis of prostate cancer
  • ASCO meeting abstract: Evaluation of the MiCheck MIA test performance in differentiating aggressive from non-aggressive prostate cancer: The MiCheck-01 prospective trial
  • ASCO meeting abstract: Glypican-1 as a novel immunotherapeutic target in prostate cancer
  • Minomic Launches US Prospective Study of MiCheck® Prostate Cancer Test
  • Minomic clinical study progresses for Miltuximab® in prostate, bladder, and pancreatic cancer
  • Minomic Announces Clinical Study Update for MILGa in Prostate, Bladder and Pancreatic Cancers

SHAREHOLDER NEWSLETTER

Minomic Shareholder Update Q4 2017

Minomic Shareholder Update Q3 2017

ANNUAL FINANCIAL STATEMENTS

Interim Financial Report for the half year to 31 December 2017

2017 Annual Financial Statement

 

FOR SHAREHOLDERS

Change of Address Form

ENQUIRIES

Address
Suite 2, Ground Floor, 
75 Talavera Road, 
Macquarie Park, NSW 2113, 
Australia

Phone
Intl: +612 9850 4000
Aust: 02 9850 4000
(Compare your time zone with Sydney here)

MORE INFO

Would you like to talk with Minomic about:

  • Partnering with us to take our products to your markets?
  • Investing in us?
  • Media or upcoming events?
  • Some feedback that you have?
  • Home
  • News
  • Shareholder Information
  • Terms of Use
  • Privacy Policy
  • Contact Us
  • Linkedin
  • Twitter
  • Google

COPYRIGHT 2017 | MINOMIC - ALL RIGHTS RESERVED